Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology
Eleonora Iascone(IRCCS Humanitas Research Hospital), Elisabetta Sauta(IRCCS Humanitas Research Hospital), Rami S. Komrokji(Moffitt Cancer Center), Saverio D’Amico(Istituti di Ricovero e Cura a Carattere Scientifico), Marilena Bicchieri(Istituti di Ricovero e Cura a Carattere Scientifico), Victor Savevski(Humanitas University), Alessia Campagna(Humanitas University), Matteo Zampini(IRCCS Humanitas Research Hospital), Gastone Castellani(University of Bologna), Matteo Brindisi(University of Calabria), Lars Bullinger(Stanford University), Eric Padron(Moffitt Cancer Center), Torsten Haferlach(Martin Luther Christian University), Cristina Astrid Tentori(Humanitas University), Federico Álvarez(Universidad Politécnica de Madrid), Ivan Ferrari(IRCCS Humanitas Research Hospital), Shahram Kordasti(Guy's Hospital), Matteo Della Porta(University of Milan), Elena Riva(Humanitas University), Gabriele Todisco(Humanitas University), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Amer M. Zeidan(Yale Cancer Center), Marta Ubezio(Humanitas University), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Laura Crisafulli(Humanitas University), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Gianluca Asti(IRCCS Humanitas Research Hospital), Alessandro Buizza(Istituti di Ricovero e Cura a Carattere Scientifico), Mattia Delleani(IRCCS Humanitas Research Hospital), Antonio Russo(Humanitas University), Pierre Fenaux(Université Paris Cité), L. Cerdá Alberich(Instituto de Investigación Sanitaria La Fe), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Nicole Pinocchio(IRCCS Humanitas Research Hospital), Alessandro Bruseghini(IRCCS Humanitas Research Hospital), António Almeida(Hospital da Luz), Francesca Ficara(Humanitas University)
Cited by 0
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
|New England Journal of Medicine|2004|997